Sarepta's First siRNA Data Sends Shares Soaring. The Fundamentals Tell a More Complicated Story.

What the data showed

The two programs in question are SRP-1001, targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1), and SRP-1003, targeting myotonic dystrophy type 1 (DM1). Approximately 16,000 individuals in the United States are diagnosed with FSHD1 and roughly 40,000 with DM1. Neither disease has a cure or an approved disease-modifying therapy.

Both programs use Sarepta's αvβ6 integrin-targeted siRNA approach (licensed exclusively from Arrowhead Pharmaceuticals), which is designed to deliver small interfering RNA directly into muscle cells by locking onto a specific protein on the cell surface. The early results showed dose-dependent muscle exposure, early biomarker effects, and favorable tolerability across both studies. After a single dose, both SRP-1001 and SRP-1003 demonstrated proof-of-concept reduction of the target protein or mRNA. The majority of adverse events were mild to moderate and were not dose dependent. No dose-limiting toxicity was observed.

Louise Rodino-Klapac, Sarepta's president of research and development, said the results "support the differentiated potential of this siRNA platform" and "strengthen our belief that this approach could meaningfully change the treatment landscape for patients with FSHD and DM1."

Why the market cared this much

The magnitude of Wednesday's move (roughly 35 percent on heavy volume) reflects the degree to which Sarepta's stock had been compressed by a series of setbacks unrelated to the siRNA pipeline. The company's gene therapy ELEVIDYS, once the primary value driver, has been dogged by a restricted FDA label, safety concerns (including fatalities that triggered a 42 percent single-day decline), and a revenue hit: fiscal Q4 2025 revenue fell roughly 33 percent year over year. Sarepta reported a Q4 EPS of negative $3.58, missing the consensus estimate of negative $0.87 by a wide margin.

In that context, any credible signal from a new therapeutic platform carries outsized weight. The siRNA data effectively reminded the market that Sarepta has a pipeline beyond ELEVIDYS: five clinical-stage RNA interference programs spanning FSHD, DM1, idiopathic pulmonary fibrosis, spinocerebellar ataxia type 2, and Huntington's disease.

The competitive angle matters, too. Novartis paid $12 billion in February to acquire Avidity Biosciences for its drugs in FSHD1 and DM1 (plus Duchenne muscular dystrophy, where Sarepta currently leads). Oppenheimer analyst Kostas Biliouris noted that muscle concentration of siRNA in patients who received Sarepta's drugs appears higher than what Avidity's testing showed, and that SRP-1001 appeared to produce a higher knockdown of the errant protein in FSHD1. He cautioned that differences between the studies make direct comparison difficult, but maintained an outperform rating with a $37 price target.

The fundamentals are still fragile

To be sure, Phase 1/2 biomarker data from a handful of patients is the earliest rung on a very long clinical ladder. Proof-of-concept knockdown is encouraging, but it is not efficacy data, and it is nowhere near the evidentiary bar required for FDA approval. The patient populations for both FSHD1 and DM1 are small, which limits peak commercial revenue even in a best-case scenario.

The financial picture reinforces the caution. Full-year fiscal 2025 revenue was $2.2 billion (up 16 percent), but profitability deteriorated sharply: Sarepta posted a GAAP net loss of $713 million, driven by surging R&D spending, inventory write-downs, and manufacturing issues. Gross margins collapsed from 81.5 percent in Q1 to 10 percent in Q4. The company ended the year with $801 million in cash and has guided toward profitability and positive cash flow in fiscal 2026, but the market has been skeptical: analyst consensus sits at Hold, with a median price target of roughly $23.50.

What comes next

The near-term catalyst is straightforward: higher-dose cohort data from both SRP-1001 and SRP-1003, expected later this year. If the dose-dependent exposure curve continues to hold without safety signals, Sarepta will have a credible case for advancing both programs into larger efficacy trials. Arrowhead Pharmaceuticals, which received a $200 million milestone payment from Sarepta tied to DM1 program progression, has a direct financial stake in the platform's success.

But the broader question for Sarepta is whether the siRNA pipeline can offset the ongoing uncertainty around ELEVIDYS. Management has framed 2026 as a pivotal year, with multiple data readouts across the siRNA portfolio and continued efforts to expand the ELEVIDYS label. The stock, even after Wednesday's rally, trades at roughly $23.77: still 86 percent below its all-time high and barely above the analyst consensus target.

Wednesday's move was a reminder that in biotech, a single data readout can reprice a stock overnight. Whether it holds depends on whether Sarepta can convert preliminary signals into the kind of durable clinical evidence that justifies a sustained re-rating. Only time will tell, but for a company that has spent the better part of two years in freefall, the siRNA data offered something investors had been short on: a reason to look forward.